<DOC>
	<DOC>NCT00488618</DOC>
	<brief_summary>This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of two treatment groups: RGH-188 or placebo</brief_summary>
	<brief_title>Study Evaluating RGH-188 in the Treatment of Patients With Acute Mania</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Male or female inpatients 18 to 65 years of age Meeting DSMIV criteria for bipolar I disorder, acute manic or mixed episode Having a total Young Mania Rating Scale (YMRS) score &gt;= 20 and a score of at least 4 on two of the following YMRS items: Irritability, Speech, Content, and Disruptive/Aggressive Behavior Patients who exhibit abnormalities on physical examination, have abnormal vitalsigns, ECG, or clinical laboratory values (such as TSH). Patients with MADRS total score &gt;= 18 at Visit 2. Patients experiencing first manic episode. Patients that have received electroconvulsive therapy (ECT) or a depot neuroleptic in the 3 months prior to Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Mania</keyword>
	<keyword>Bipolar I Disorder</keyword>
	<keyword>Acute Mania Associated with Bipolar I Disorder</keyword>
</DOC>